| 前收盘价格 | 1.97 |
| 收盘价格 | 1.99 |
| 成交量 | 28,650 |
| 平均成交量 (3个月) | 66,780 |
| 市值 | 696,168,640 |
| 预期市盈率 (P/E Forward) | 53.48 |
| 价格/销量 (P/S) | 0.830 |
| 股市价格/股市净资产 (P/B) | 0.880 |
| 52周波幅 |
| 营业毛利率 | -26.26% |
| 营业利益率 (TTM) | -9.91% |
| 稀释每股收益 (EPS TTM) | -0.690 |
| 季度收入增长率 (YOY) | -4.20% |
| 总债务/股东权益 (D/E MRQ) | 52.48% |
| 流动比率 (MRQ) | 2.03 |
| 营业现金流 (OCF TTM) | 34.59 M |
| 杠杆自由现金流 (LFCF TTM) | -90.11 M |
| 资产报酬率 (ROA TTM) | -2.42% |
| 股东权益报酬率 (ROE TTM) | -20.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Evotec SE | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.17 |
|
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Core |
| 机构持股比例 | 2.56% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Optiver Holding B.V. | 31 Mar 2026 | 283,576 |
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Snowden Capital Advisors Llc | 31 Mar 2026 | 24,409 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合